Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  2009-02-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/jnnp.2008.168211PMID 19246476
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism

  2008cited by this paper
• Consensus Statement of the Movement Disorder Society on Tremor

  2008cited by this paper
• Sex and Parkinson’s disease: a world of difference?

  2007cited by this paper
• Heterogeneity in male to female risk for Parkinson’s disease

  2007influential reference
• Gender disparities in Parkinson’s disease

  2006cited by this paper
• Gender differences in Parkinson’s disease

  2006influential reference
• Pilot study of the incidence and prognosis of degenerative Parkinsonian disorders in Aberdeen, United Kingdom: Methods and preliminary results

  2006cited by this paper
• Progression of motor impairment and disability in Parkinson disease

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005cited by this paper
• Incidence of parkinsonism and Parkinson disease in a general population: The Rot terdam Study

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study.

  2004cited by this paper
• Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain

  2004cited by this paper
• Incidence of parkinsonism and Parkinson disease in a general population

  2004cited by this paper
• Systematic review of incidence studies of Parkinson's disease

  2003influential reference
• Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system

  2003cited by this paper
• Is there a connection between estrogen and Parkinson's disease?

  2002cited by this paper
• The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.

  2002cited by this paper
• Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics

  2002cited by this paper
• Footprints of coagulopathy

  2002cited by this paper
• Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system.

  2001cited by this paper
• The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system.

  2001cited by this paper
• Motor impairment in PD

  2000cited by this paper
• Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging.

  2000cited by this paper
• Influence of strict, intermediate, and broad diagnostic criteria on the age‐ and sex‐specific incidence of Parkinson's disease

  2000cited by this paper
• Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers

  2000cited by this paper
• Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

  2000cited by this paper
• [The Unified Parkinson's Disease Rating Scale].

  2000cited by this paper
• [Incidence of idiopathic and secondary Parkinson disease in Navarre. Population-based case registry].

  1999cited by this paper
• Accuracy of diagnosis in patients with presumed Parkinson's disease.

  1999cited by this paper
• Diagnostic criteria for Parkinson disease.

  1999cited by this paper
• Changing epidemiology of Parkinson’s disease in southwestern Finland

  1999cited by this paper
• Consensus statement on the diagnosis of multiple system atrophy

  1998cited by this paper
• Inhibitory NANC neurotransmission in choledocho-duodenal junction of rabbits--a possible role of PACAP.

  1998cited by this paper
• The role of spectroscopy in parkinsonism

  1998cited by this paper
• Diagnosis and management of dementia.

  1997cited by this paper
• Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)

  1996cited by this paper
• The epidemiology of Parkinson's disease in the county of Rogaland, Norway

  1995cited by this paper
• The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993.

  1995cited by this paper
• A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation

  1994cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• Book Review: Third Symposium on Parkinson's Disease

  1970cited by this paper
• Projection technique for evaluating surgery in Parkinson’s disease

  1969cited by this paper
• Parkinsonism

  1967cited by this paper

• Amalgamation of postbiotic, polysaccharide and plant flavonoid in nanostructured lipid carrier for treatment of rotenone-induced Parkinson's disease

  2026cites this paper
• Dementia risk prediction in early Parkinson's disease: Validation and genetic integration of the Montreal Parkinson risk of dementia scale (MoPaRDS)

  2025cites this paper
• Beta-adrenoceptor drugs and progression to Parkinson’s disease milestones in a large pooled incident cohort

  2025cites this paper
• Sex differences in neurological disorders: Insights from ischemic stroke, Parkinson's disease, and multiple sclerosis.

  2025cites this paper
• Cerebrospinal Fluid Phosphorylated Alpha‐Synuclein in Newly Diagnosed Parkinson's Disease

  2025cites this paper
• CHAS infers cell type-specific signatures in bulk brain histone acetylation studies of neurological and psychiatric disorders.

  2025cites this paper
• Relationship of cognitive decline with glucocerebrosidase activity and amyloid‐beta 42 in DLB and PD

  2025influential citation
• Circulating cell-free DNA as predictors of Parkinson's disease.

  2025cites this paper
• Sexual Dimorphism in Levodopa‐Induced Dyskinesia Following Parkinson's Disease: Uncharted Territory

  2025cites this paper
• Sex differences in 6-OHDA lesioned rats in a preclinical model for Parkinson's disease.

  2025cites this paper
• Race and ethnicity matter! Moving Parkinson’s risk research towards diversity and inclusiveness

  2025influential citation
• Gender discrepancies and differences in motor and non-motor symptoms, cognition, and psychological outcomes in the treatment of Parkinson’s disease with subthalamic deep brain stimulation

  2024cites this paper
• Detailed Analysis of the Palmomental Reflex and Its Clinical Significance

  2024cites this paper
• Mitochondrial complex I deficiency stratifies idiopathic Parkinson’s disease

  2024cites this paper
• Nigral transcriptomic profiles in Engrailed-1 hemizygous mouse models of Parkinson’s disease reveal upregulation of oxidative phosphorylation-related genes associated with delayed dopaminergic neurodegeneration

  2024cites this paper
• Update: Descriptive epidemiology of Parkinson disease.

  2024cites this paper
• Combination therapy of phytonanomedicine and post-biotic for the management of Parkinson’s disease

  2024cites this paper
• Risk factors and evolution of weight loss in Parkinson's disease: A 9-year population-based study.

  2024cites this paper
• Prevalence of Parkinson’s disease in Pakistan – A Systematic Review

  2024cites this paper
• Orthostatic Hypotension and Risk of Mild Cognitive Impairment and Dementia in Parkinson's Disease

  2024cites this paper
• Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson’s Disease

  2024cites this paper
• Genetic Modifiers of LRRK2 Parkinson's Disease: A Replication Study in Arab‐Berbers

  2024cites this paper
• Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid

  2024cites this paper
• Opening avenues for treatment of neurodegenerative disease using post-biotics: Breakthroughs and bottlenecks in clinical translation.

  2024cites this paper
• Revealing the mechanisms of blood–brain barrier in chronic neurodegenerative disease: an opportunity for therapeutic intervention

  2024cites this paper
• Single-nucleus transcriptomics reveals disease- and pathology-specific signatures in α-synucleinopathies

  2024cites this paper
• The Mean Shape under the Relative Curvature Condition

  2024influential citation
• Early GCase activity is a predictor of long-term cognitive decline in Parkinson’s disease

  2023cites this paper
• Identification of diagnostic and prognostic biomarkers of PD using a multiplex proteomics approach.

  2023cites this paper
• Seed Amplification Assay as a Diagnostic Tool in Newly-Diagnosed Parkinson’s Disease

  2023cites this paper
• Incidence of Parkinson’s disease and modifiable risk factors in Korean population: A longitudinal follow-up study of a nationwide cohort

  2023cites this paper
• Blood-Brain Barrier and Neurovascular Unit Dysfunction in Parkinson's Disease: From Clinical Insights to Pathogenic Mechanisms and Novel Therapeutic Approaches.

  2023cites this paper
• Neurodegenerative Diseases: Their Onset, Epidemiology, Causes and Treatment

  2023cites this paper
• Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia

  2023cites this paper
• Neuroprotective role for RORA in Parkinson’s disease revealed by analysis of post-mortem brain and a dopaminergic cell line

  2023cites this paper
• Sex differences in gastrointestinal dysfunction among patients with Parkinson’s disease

  2023cites this paper
• Nigral Transcriptomic Profiles in Engrailed-1 Hemizygous Mouse Models of Parkinson’s Disease Reveal Upregulation of Oxidative Phosphorylation-Related Genes Associated with Resistance to Dopaminergic Neurodegeneration

  2023cites this paper
• Developmental exposure to the Parkinson’s disease-associated organochlorine pesticide dieldrin alters dopamine neurotransmission in α-synuclein pre-formed fibril (PFF)-injected mice

  2023cites this paper
• Three-Dimensional Analysis of Sex- and Gonadal Status- Dependent Microglial Activation in a Mouse Model of Parkinson’s Disease

  2023cites this paper
• Cognitive Profile in Parkinson’s Disease Dementia Patients with Low versus Normal Cerebrospinal Fluid Amyloid Beta

  2023cites this paper
• Inflammatory Biomarkers in Newly Diagnosed Patients With Parkinson Disease and Related Neurodegenerative Disorders

  2023cites this paper
• Not every estimate counts – evaluation of cell composition estimation approaches in brain bulk tissue data

  2023cites this paper
• Frailty in Parkinson's disease and its association with early dementia: A longitudinal study.

  2022cites this paper
• Early Forms of α-Synuclein Pathology Are Associated with Neuronal Complex I Deficiency in the Substantia Nigra of Individuals with Parkinson’s Disease

  2022cites this paper
• GBA and APOE Impact Cognitive Decline in Parkinson’s Disease: A 10-Year Population-Based Study

  2022cites this paper
• Change in the incidence of Parkinson’s disease in a large UK primary care database

  2022cites this paper
• Age at onset as stratifier in idiopathic Parkinson’s disease – effect of ageing and polygenic risk score on clinical phenotypes

  2022cites this paper
• Parkinson’s disease clinical milestones and mortality

  2022cites this paper
• Nutrition impact symptoms and the risk of malnutrition in people with Parkinson's disease: a cross-sectional study.

  2022cites this paper
• Emerging roles of leptin in Parkinson's disease: chronic inflammation, neuroprotection and more?

  2022cites this paper
• Sex differences in Parkinson's Disease: An emerging health question

  2022cites this paper
• Sex and gender differences in movement disorders: Parkinson's disease, essential tremor, dystonia and chorea.

  2022cites this paper
• Effectiveness of therapeutic massage for improving motor symptoms in Parkinson's disease: A systematic review and meta-analysis

  2022cites this paper
• Cannabis use in Parkinson’s disease—A nationwide online survey study

  2022cites this paper
• Parkinson’s disease clinical milestones and mortality

  2022cites this paper
• Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways.

  2021cites this paper
• The impact of common genetic variants in cognitive decline in the first seven years of Parkinson's disease: a longitudinal observational study.

  2021cites this paper
• Lack of Association Between GBA Mutations and Motor Complications in European and American Parkinson’s Disease Cohorts

  2021cites this paper
• Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain

  2021cites this paper
• Ultra-deep whole genome bisulfite sequencing reveals a single methylation hotspot in human brain mitochondrial DNA

  2021cites this paper
• Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease

  2021cites this paper
• Letter to the editor in response to the letter from the EPIPARK Study Group regarding the publication ʻProgression of fatigue in Parkinson's disease ‐ a 9‐year follow‐upʼ (Eur J Neurol 2021. doi:10.1111/ene.14520)

  2021cites this paper
• Early-Onset Parkinsonism and Early-Onset Parkinson’s Disease: A Population-Based Study (2010-2015)

  2021cites this paper
• Whole Clinic Research Enrollment in Parkinson’s Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study

  2021cites this paper
• Empirical evaluation of the sensitivity of background incidence rate characterization for adverse events across an international observational data network

  2021cites this paper
• Association of SNCA Parkinson's Disease Risk Polymorphisms With Disease Progression in Newly Diagnosed Patients

  2021cites this paper
• Altered transcriptome-proteome coupling indicates aberrant proteostasis in Parkinson’s disease

  2021cites this paper
• Meta-analysis of whole-exome sequencing data from two independent cohorts finds no evidence for rare variant enrichment in Parkinson disease associated loci

  2020cites this paper
• Biological Sex and Sex Hormone Impacts on Deficits in Episodic-Like Memory in a Rat Model of Early, Pre-motor Stages of Parkinson's Disease

  2020cites this paper
• Network Protein Interaction in Parkinson’s Disease and Periodontitis Interplay: A Preliminary Bioinformatic Analysis

  2020cites this paper
• Genetic risk scores and hallucinations in patients with Parkinson disease

  2020cites this paper
• Progression of fatigue in Parkinson’s disease – a 9‐year follow‐up

  2020cites this paper
• Impulsive and compulsive behaviors in Parkinson's disease: Impact on quality of and satisfaction with life, and caregiver burden.

  2020cites this paper
• Relationship between Blood and Standard Biochemistry Levels with Periodontitis in Parkinson’s Disease Patients: Data from the NHANES 2011–2012

  2020cites this paper
• Differential transcript usage in the Parkinson’s disease brain

  2020cites this paper
• Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of α-synuclein-preformed fibril-induced toxicity and motor deficits

  2020cites this paper
• Is insulin-like growth factor-1 involved in Parkinson’s disease development?

  2020cites this paper
• Sex differences in movement disorders

  2020cites this paper
• Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease

  2020cites this paper
• Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease.

  2020cites this paper
• Impulse Control Disorders in Parkinson’s disease

  2020cites this paper
• Gastrectomy and Nigrostriatal Dopaminergic Depletion in De Novo Parkinson’s Disease

  2019cites this paper
• The value of cerebrospinal fluid α‐synuclein and the tau/α‐synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology

  2019cites this paper
• α-Synuclein

  2019cites this paper
• Sex-Specific Patient Journeys in Early Parkinson's Disease in the Netherlands

  2019cites this paper
• Dysregulation of histone acetylation and decoupling from transcription in Parkinson’s disease

  2019cites this paper
• Incidence and Mortality of Parkinson’s Disease in Estonia

  2019cites this paper
• Combinatory microRNA serum signatures as classifiers of Parkinson's disease.

  2019cites this paper
• State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease

  2019cites this paper
• Evolution of impulsive–compulsive behaviors and cognition in Parkinson’s disease

  2019cites this paper
• Sex differences in the progressive model of parkinsonism induced by reserpine in rats

  2019cites this paper
• Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms

  2019cites this paper
• Orthostatic hypotension in Parkinson disease

  2019influential citation
• Common gene expression signatures in Parkinson’s disease are driven by changes in cell composition

  2019cites this paper
• Time interval to definite diagnosis of Parkinsonism

  2019cites this paper
• Genome-wide dysregulation of histone acetylation in the Parkinson’s disease brain

  2019cites this paper
• Luteolin-7-O-glucoside protects dopaminergic neurons by activating estrogen-receptor-mediated signaling pathway in MPTP-treated mice.

  2019cites this paper
• Widespread sex dimorphism in aging and age-related diseases

  2019cites this paper
• Comorbid Depression and Psychosis in Parkinson’s Disease: A Report of 62,783 Hospitalizations in the United States

  2019cites this paper
• Aggravated behavioral and neurochemical deficits and redox imbalance in mice with enhanced neonatal iron intake: improvement by biochanin A and role of microglial p38 activation

  2019cites this paper